

| Corresponding author(s): | Lawrence S. Prince |
|---------------------------|--------------------|
| Last updated by author(s) | : April 23, 2020 |

Reporting Summary

Nature Research wishes to improve the reproducibility of the work that we publish. This form provides structure for consistency and transparency in reporting. For further information on Nature Research policies, see <u>Authors & Referees</u> and the <u>Editorial Policy Checklist</u>.

| Statistics | |
|---|--|
| For all statistical analys | es, confirm that the following items are present in the figure legend, table legend, main text, or Methods section. |
| n/a Confirmed | |
| ☐ ☐ The exact sam | $^{\circ}$ pple size (n) for each experimental group/condition, given as a discrete number and unit of measurement |
| A statement of | on whether measurements were taken from distinct samples or whether the same sample was measured repeatedly |
| The statistical Only common to | test(s) used AND whether they are one- or two-sided ests should be described solely by name; describe more complex techniques in the Methods section. |
| A description | of all covariates tested |
| A description | of any assumptions or corrections, such as tests of normality and adjustment for multiple comparisons |
| A full descript AND variation | ion of the statistical parameters including central tendency (e.g. means) or other basic estimates (e.g. regression coefficient) (e.g. standard deviation) or associated estimates of uncertainty (e.g. confidence intervals) |
| For null hypot | thesis testing, the test statistic (e.g. F , t , r) with confidence intervals, effect sizes, degrees of freedom and P value noted a sexact values whenever suitable. |
| For Bayesian | analysis, information on the choice of priors and Markov chain Monte Carlo settings |
| For hierarchic | al and complex designs, identification of the appropriate level for tests and full reporting of outcomes |
| Estimates of e | effect sizes (e.g. Cohen's d, Pearson's r), indicating how they were calculated |
| I | Our web collection on <u>statistics for biologists</u> contains articles on many of the points above. |
| Software and o | ode |
| Policy information abo | ut <u>availability of computer code</u> |
| Data collection | No proprietary software was need to obtain publicly available data from GEO. |
| Data analysis | Details on software programs, versions, and sources are included in the manuscript text. |
| For manuscripts utilizing custom algorithms or software that are central to the research but not yet described in published literature, software must be made available to editors/reviewers. We strongly encourage code deposition in a community repository (e.g. GitHub). See the Nature Research guidelines for submitting code & software for further information. | |
| Data | |
| Accession codes, unA list of figures that | ut <u>availability of data</u> include a <u>data availability statement</u> . This statement should provide the following information, where applicable: ique identifiers, or web links for publicly available datasets have associated raw data restrictions on data availability |
| Our data have been subn | nitted through the GEO and will be made publicly available upon publication of the manuscript. |
| Field-speci | fic reporting |
| Please select the one b | elow that is the best fit for your research. If you are not sure, read the appropriate sections before making your selection. |
| \times Life sciences | Behavioural & social sciences Ecological, evolutionary & environmental sciences |

For a reference copy of the document with all sections, see <u>nature.com/documents/nr-reporting-summary-flat.pdf</u>

Life sciences study design

Study protocol

| All studies must dis | close on these points even when the disclosure is negative. | | |
|--------------------------------|--|--|--|
| Sample size | This study was a first of its kind. As a result, we had no previous information regarding standard deviation or effect of covariates on gene expression levels. We approximated needing around 100 patients for the study, knowing that some samples would not yield sufficient numbers of cells and therefore mRNA. We were able to obtain samples from 113 patients. | | |
| Data exclusions | No data were excluded from our study. | | |
| Replication | Replicate measures were only performed for real time PCR measurements in Figure 1d. | | |
| Randomization | Patients and samples were not assigned to different experimental groups up front. | | |
| Blinding | While blinding was not required for this study, data analysts were not aware of disease-related covariates at the time of initial analysis. Disease groups were assigned numerical values to mask the clinical variables. | | |
| We require information | g for specific materials, systems and methods on from authors about some types of materials, experimental systems and methods used in many studies. Here, indicate whether each material, | | |
| | ed is relevant to your study. If you are not sure if a list item applies to your research, read the appropriate section before selecting a response. | | |
| | perimental systems Methods n/a Involved in the study | | |
| n/a Involved in th Antibodies | ChIP-seq | | |
| Eukaryotic | | | |
| Palaeontole | | | |
| Animals an | d other organisms | | |
| | earch participants | | |
| Clinical dat | | | |
| Human rese | arch participants | | |
| | about <u>studies involving human research participants</u> | | |
| Population chara | | | |
| · | weight at 36 wk corrected age, diagnosis of pneumonia, respiratory support at 36 wk, hospital days, days of mechanical ventilation, CPAP, nasal cannula oxygen, maternal chorioamnionitis, maternal hypertension, maternal pre-eclampsia, pulmonary hemorrhage, timing of initial intubation. | | |
| Recruitment | Study participants were premature infants less than 30 weeks gestation, who were intubated for mechanical ventilation due to respiratory distress syndrome. Samples were collected from participants weekly as long as they remained intubated. Patients were recruited from the neonatal intensive care units at Vanderbilt University, Rady Children's Hospital, and the University of California, San Diego. Some of the participating infants at Vanderbilt were enrolled in the Prematurity and Respiratory Outcome Program (PROP) at Vanderbilt University Medical Center (NCT01460576). | | |
| Ethics oversight | This study was approved by the Institutional Review Boards at Vanderbilt University and the University of California, San Diego. Of note, Rady Children's Hospital and the University of California, San Diego use a shared IRB structure. | | |
| Note that full informa | tion on the approval of the study protocol must also be provided in the manuscript. | | |
| Clinical data | | | |
| * | about <u>clinical studies</u> I comply with the ICMJE <u>guidelines for publication of clinical research</u> and a completed <u>CONSORT checklist</u> must be included with all submissions | | |
| Clinical trial regis | | | |

Study protocols were reviewed and approved by the Institutional Review Boards at Vanderbilt University and the University of

California, San Diego. Of note, Rady Children's Hospital and the University of California, San Diego use a shared IRB structure.

Data collection De-identified clinical data and demographic data approved by the IRB were obtained from the electronic medical record and stored in a secured, encrypted database.

Outcomes

For this non-interventional study, clinical outcome data approved by the IRB were obtained from the electronic medical record and stored in a secured, encrypted database.